NASDAQ:IMMX | Free Cash Flow | Immix Biopharma, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$9.83M$32,486.00-$9.86M
2025-12-31-$11.03M$165,126.00-$11.19M
2025-03-31-$1.69M$67,713.00-$1.75M
2024-12-31-$1.48M$507,151.00-$1.98M
2024-03-31-$3.83M$301,913.00-$4.13M
2023-12-31-$2.68M$13,177.00-$2.69M
2023-03-31-$2.09M
2022-12-31-$3.9M
2022-03-31-$1.49M
2021-12-31-$1.11M$0.00-$1.11M
2021-03-31-$266,446.00$802.00-$267,248.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$23.93M$732,925.00-$24.66M
2024-12-31-$14.6M$1.18M-$15.77M
2023-12-31-$11.37M$52,089.00-$11.42M
2022-12-31-$7.41M
2021-12-31-$1.59M$802.00-$1.59M
2020-12-31-$404,694.00